A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
← catalyst calendarNCT05995964 · readout in 60 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
340estimated
Sites
98
Countries
Australia, Canada, China +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-22 | actual | When the study began enrolling |
| Primary completion | 2026-10-19 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-08 | estimated | The whole study's end, after follow-up |
| First posted | 2023-08-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis
Interventions
- Drug: PF-07275315
- Drug: PF-07264660
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFThe number of participants achieving ≥75% improvement in EAS175 from baseline at week16.
measured Week 16
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed